Whilst low-rely MBL not often progresses to CLL, superior-count MBL progresses to CLL requiring therapy at a fee of one% to two% every year. High-count MBL is distinguished from Rai 0 CLL determined by whether or not the B-cell rely is higher than or under five × 109/L. Though people today wit